Skip to main content
. 2023 Jun 26;21:226. doi: 10.1186/s12916-023-02943-2

Table 2.

Tumor response

Response All (n = 53)
Best overall response, n (%)
 Complete response 4 (7.5)
 Partial response 30 (56.6)
 Stable disease 6 (11.3)
 Progressive disease 7 (13.2)
 Not evaluable 6 (11.3)
Clinical benefit rate (95% CI) 71.7% (57.7%, 83.2%)
Objective response rate (95% CI) 64.2% (49.8%, 76.9%)

CI confidence interval